Cystic Fibrosis Market Detail Analysis | Focusing on Major Players as Vertex Pharmaceuticals, F. Hoffmann-La Roche, etc

MarketResearchFuture.com (MRFR) in its recently Announced study report asserts that the “Global Cystic Fibrosis Market” growing further will reach USD 1,192.2 million by 2022, registering 13.5% CAGR Along with Top Companies, Mega Trends.

Cystic Fibrosis Market - Overview

According to a recent study report published by the Market Research Future analysts, the global cystic fibrosis market is growing at a double digit CAGR. The major growth in the cystic fibrosis market was observed with the introduction of Kalydeco drug by Vertex pharmaceutical in 2012. There has been constant development of new drugs and therapies for treating cystic fibrosis.

Cystic fibrosis foundation (CFF) has always been in support of the companies involved in the research and development of the cystic fibrosis drugs.

The financial support from CFF is influential in the growth of the cystic fibrosis market worldwide. That being said, there are few hurdles as well in growth of this market. Currently there are approximately 1900 identified CFTR mutations that are responsible for the development of the disease condition.

Request for Sample Report at https://www.marketresearchfuture.com/sample_request/1825

Many are yet to be identified. At present, treatments are available for nearly half the mutations. CF being the rare disease, and due to the limited information available, the extensive research is required. The research and development cost for the cystic fibrosis is very high leading to the massive prices of the end products. High cost of the drugs and treatments is one of the factors that hinder the growth of the cystic fibrosis market.

Top Players:

Vertex Pharmaceuticals

F. Hoffmann-La Roche

AbbVie

Gilead Sciences

Novartis

Genentech

Pharmaxis and others.

Segmentation:

The global cystic fibrosis market is segmented on the basis of treatment method. Treatment method is further segmented into medication, devices, and other treatments.

Global Cystic Fibrosis Market - Regional Analysis

Cystic fibrosis can occur in both genders as well as in all ethnic groups and races. However the incidences of cystic fibrosis varies across the globe. Cystic fibrosis is more common among the Caucasians. Hence the disease is more prevalent in North America, Europe, and Australia. However cystic fibrosis can also affect Latinos, American Indians, African, and Middle Eastern population.

North America is one of the majorly affected region by the deadly disease cystic fibrosis. The United States is among the countries with highest incidence rates of cystic fibrosis. According to cystic fibrosis foundation, more than 30,000 patients are living with cystic fibrosis in the United States. Nearly, 1000 new cystic fibrosis cases are diagnosed each year. According to CFF’s national patient registry, the median age of the person with cystic fibrosis is currently 33.4 years. The average life expectancy of the CF patients has increased significantly as compared to the patients 30 years back.

Ask Any Question at https://www.marketresearchfuture.com/enquiry/1825

Global Cystic Fibrosis Market - Competitive Analysis

The global market for cystic fibrosis is dominated by American pharmaceutical company Vertex Pharmaceuticals Incorporated. With two FDA approved CFTR modulator drugs Kalydeco & Orkambi, Vertex Pharmaceuticals secured a top spot with the market share of 46% in the global cystic fibrosis market. Kalydeco and Orkambi are the drugs that affect the disease at a genetic level where as all the other drugs from different companies deal with the disease symptoms and associated problems. Currently there is no competition for the Kalydeco and Orkambi.

Moreover the Vertex is on the verge of developing their next and better drug “triple combo” which is expected to cover 90% of the total identified CFTR mutations. This development is the strong reason for Vertex pharmaceutical to be on top of the table in the near future as well.

Apart from the Vertex, there are some companies which are manufacturing different drugs for the treatment for the cystic fibrosis. These companies have drug products such as Roche- Pulmozyme, Abbvie- Creon, Gilead- Cayston, Novartis- TOBI Podhaler, Allergan- Zenpep, Chiesi- Pertzye, and few others. As these products help patients in managing the cystic fibrosis symptoms and are consumed daily, these companies have fair amount of share in the market. Additionally, there are other companies which such as Pharmaxis, PTC therapeutics, Janssen Pharmaceuticals, Inc which are involved in the development of the treatments for the symptoms of cystic fibrosis.

Major TOC of Cystic Fibrosis Market Research Report- Global Forecast till 2022

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 MARKET DYNAMICS

4 MARKET FACTOR ANALYSIS

5 GLOBAL CYSTIC FIBROSIS MARKET, BY DIAGNOSTIC TEST

6 GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT

7 GLOBAL CYSTIC FIBROSIS MARKET, BY DRUG TYPE

8 GLOBAL CYSTIC FIBROSIS MARKET, BY REGION

9 COMPETITIVE LANDSCAPE

10 COMPANY PROFILE

Check Discount at https://www.marketresearchfuture.com/check-discount/1825

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.